摘要

This study aimed to review and quantitatively analyze (1) the association of aplastic anemia (AA) with human leukocyte antigen (HLA)-DRB1* 15 and HLA-DRB1* 15:01 polymorphisms and (2) the association of HLA-DRB1* 15 and HLA-DRB1* 15:01 polymorphisms with response to immunosuppressive therapy (IST) in AA. Published studies have reported conflicting and heterogeneous results regarding the association of HLA-DRB1* 15 and HLA-DRB1* 15:01 polymorphisms with response to IST in AA. The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature, Wang-fang and Chinese Social Sciences Citation Index databases were searched. All relevant publications were searched through December 2015. Odds ratio (OR), risk ratio (RR), and 95% confidence intervals (CI) for the comparison between case-control or cohort studies were evaluated. Finally, 24 articles were identified. For HLA-DRB1* 15 and HLA-DRB1* 15:01, the OR (95% CI) was 2.24(1.33-3.77), P < 0.01 and 2.50(1.73-3.62), P < 0.01, respectively; and the overall pooled RR was 1.72 (1.30-2.29), P < 0.01 and 1.59 (1.29-1.96), P < 0.01, respectively. Statistical evidence showed no publication bias (P > 0.05). Sensitivity analyses revealed that the results were statistically robust. The meta-analysis suggested that HLA-DRB1* 15 and HLA-DRB1* 15:01 polymorphisms might be associated with increased AA risk in Asians. IST might be more effective in HLA-DRB1* 15(+) and HLA-DRB1* 15:01(+) Asian patients with AA than in HLA-DRB1* 15- and HLA-DRB1* 15:01-Asian patients with AA. Future studies with adequate methodological quality on gene-gene and gene-environment interactions and gene treatment may yield valid results.

  • 出版日期2016-9-9
  • 单位浙江省人民医院